Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › LXEO

Lexeo Therapeutics

LXEO Pending acquisition Rare disease Lead: Phase 2 6 Biotech Distilled articles ↓ 27 filings & releases ↓ Cash $92.8M (Jun 30, 2026) ↓ 6 verdicts ↓ 1 timing quote ↓
CardiovascularNeurology Gene TherapyNucleic AcidProteinSmall Molecule

Market cap $237M 82.0M shares (10-Q, Aug 10, 2026) × $2.89 close Nov 6, 2026

Most recent annual filing: 2026-03-30

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. Mantle transaction corporate updateNov 16, 2026Mantle transaction corporate update, Nov 16, 2026, routine
  2. LX3010 / LX3030 LX3050 LX3070Early 2027LX3010 / LX3030 LX3050 LX3070, Early 2027, notable
  3. Next FA development candidate IND2027Next FA development candidate IND, 2027, notable
  4. LX2006 FA pivotal topline2H 2027LX2006 FA pivotal topline, 2H 2027, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (12 active programs)

Technology platforms

Sf9-baculovirus AAV manufacturing platform

Optimized Sf9 baculovirus suspension-based AAV manufacturing process offering improved scalability and reduced cost while maintaining purity and potency, supporting cardiac genetic medicine programs.

Capital (as filed)

Cash
$92.8M cash and cash equivalents · Jun 30, 2026 (10-Q)
Short-term investments
$119M Jun 30, 2026
Long-term investments
$22.5M Jun 30, 2026
Operating cash flow
−$17.6M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$234M cash, runway 2028 per the update of Sep 22, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (6)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (6 calls)

Every verdict Biotech Distilled has published on Lexeo Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2025-12-22 Watch Lexeo Therapeutics (LXEO): Scientific Due Diligence for Lead and Pipeline Products Regulatory tailwinds (FDA acceptance of manufacturing switch and surrogate endpoint) and 3-year cash runway offer favorable risk/reward, but the author is waiting for the January LX2020 safety dataset and pivotal protocol clarity before committing capital.
  2. 2026-01-12 Buy speculative UPDATE: Lexeo (LXEO) Drops 25%+ on "Positive" Data – Why Did the Market Halt on the LX2020 Readout? The market is overreacting to ambiguous efficacy while ignoring definitive protein expression; the scientific thesis remains intact and the J&J collaboration provides a safety net.
  3. 2026-06-15 Speculative buy speculative UPDATE: Lexeo Therapeutics (LXEO) - The Pivotal Protocol Lands, and the FDA Just Dropped the Hardest Endpoint Three of four major regulatory questions closed favorably (surrogate endpoint accepted as sole primary, randomized design accepted, Sf9 commercial process cleared), the pivotal trial is powered against an effect size the drug has already exceeded, and the stock is 26% lower than the initial Watch List call.
  4. 2026-08-06 Speculative buy speculative UPDATE: Lexeo Therapeutics (LXEO) - The FDA Just Graded the Data the Market Failed RMAT designation confirms the FDA read the January interim LX2020 data as preliminary evidence of clinical benefit, restoring LX2020 from a write-off to a call option with a named expiry, while LX2006 remains the value driver with its pivotal on track.
  5. 2026-08-13 Speculative buy speculative UPDATE: Lexeo Therapeutics (LXEO) - The Quiet ATM Operational execution matched the plan (first patient dosed, RMAT collected, G&A cut) but the undisclosed ATM sales of ~10% of float at depressed prices modestly worsen the per-share upside without breaking the core thesis.
  6. 2026-09-23 Speculative buy speculative UPDATE: Lexeo Therapeutics (LXEO) - The $8.3 Million Pipeline and the Market's Shrug The Mantle acquisition costs roughly six weeks of burn, improves SUNRISE-FA 2 enrollment visibility, and adds cheap optionality on CNS FA and the redosing problem, but the 'focused cardiovascular specialist' framing no longer holds and the ATM overhang persists.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (27)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 11, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

13 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)